GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EirGenix Inc (ROCO:6589) » Definitions » Institutional Ownership

EirGenix (ROCO:6589) Institutional Ownership : 4.41% (As of Nov. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is EirGenix Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, EirGenix's institutional ownership is 4.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, EirGenix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, EirGenix's Float Percentage Of Total Shares Outstanding is 0.00%.


EirGenix Institutional Ownership Historical Data

The historical data trend for EirGenix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EirGenix Institutional Ownership Chart

EirGenix Historical Data

The historical data trend for EirGenix can be seen below:

2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31
Institutional Ownership 4.38 4.40 4.44 4.43 4.47 4.48 4.46 4.46 4.40 4.41

EirGenix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


EirGenix Business Description

Traded in Other Exchanges
N/A
Address
No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in biosimilar and new drug research and development as well as biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein characterisation, as well as PIC/S facilities to provide clinical trial drug production. Its services include Cell Line Development, Process Development, Analytical Science and Quality Control, cGMP manufacturing-mammalian system, cGMP manufacturing-microbial system, and Antibody Drug Conjugate.

EirGenix Headlines

No Headlines